Orphan Medical Xyrem Scripts Average 500 Per Week For Last Six Weeks
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm hopes positive Phase IIIb data from excessive daytime sleepiness trial will boost script numbers ahead of sNDA filing in second half of year. SXB-15 trial shows statistically significant results for primary and secondary endpoints.